TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement.
NEW YORK, July 30, 2025 /PRNewswire/ -- Expert Consumers has recognized the Corporate Finance Institute® (CFI) as a leading provider of FP&A certification for professionals...
NEW YORK, July 29, 2025 /PRNewswire/ -- Artificial intelligence (AI) is projected to become a mainstream finance and accounting tool, according to a recent...
WINDSOR, Conn. and LONDON, July 29, 2025 /PRNewswire/ -- Quest Global, a leading global product engineering services company, is proud to announce its multi-year...
"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms."
BOSTON,...
"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms."
BOSTON,...